title: [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].
authors.forename: Chihiro
authors.initials: C
authors.lastname: Tamaki
authors.forename: Masakazu
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Iwamoto
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Glaesner
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004763:Glucagon-Like Peptides / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D007273:Injections, Intramuscular / Q000295:instrumentation; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D011995:Recombination, Genetic; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D007141:Immunoglobulin Fc Fragments; D011993:Recombinant Fusion Proteins; D004763:Glucagon-Like Peptides; C555680:dulaglutide; D000097789:Glucagon-Like Peptide-1 Receptor Agonists